Search research articles
Contact Us
Filters
Showing results (151-160 of 176) with videos related to
Page
of 18
Sort By:
European Urology
|
December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan M Basch, Mark Scholz, Johann S de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 27, 2025
TRIM63 Overexpression in FISH-Negative MiTF Family Altered Renal Cell Carcinoma (MiTF RCC)
Rahul Mannan, Ying-Bei Chen, Xiaoming Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Himisha Beltran, Clara Oromendia, Daniel C Danila, et al.
Cancer Discovery
|
November 14, 2024
The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Yi Bao, Gabriel Cruz, Yuping Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Eclinicalmedicine
|
June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study
Cassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
JCO Precision Oncology
|
February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
David M Hyman, Ben Tran, Luis Paz-Ares, et al.
Clinical Genitourinary Cancer
|
August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
Brian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Page
of 18
Search research articles
Search
Showing results (151-160 of 176) with videos related to
Sort By:
Page
of 18
European Urology
|
December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan M Basch, Mark Scholz, Johann S de Bono, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 28, 2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study
Emmanuel S Antonarakis, Josep M Piulats, Marine Gross-Goupil, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 16, 2022
Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
August 27, 2025
TRIM63 Overexpression in FISH-Negative MiTF Family Altered Renal Cell Carcinoma (MiTF RCC)
Rahul Mannan, Ying-Bei Chen, Xiaoming Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 21, 2018
A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers
Himisha Beltran, Clara Oromendia, Daniel C Danila, et al.
Cancer Discovery
|
November 14, 2024
The UBA1-STUB1 Axis Mediates Cancer Immune Escape and Resistance to Checkpoint Blockade
Yi Bao, Gabriel Cruz, Yuping Zhang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 6, 2012
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
Toni K Choueiri, Ulka Vaishampayan, Jonathan E Rosenberg, et al.
Eclinicalmedicine
|
June 12, 2023
Metastatic renal cell carcinoma to the pancreas and other sites-a multicenter retrospective study
Cassandra Duarte, Junxiao Hu, Benoit Beuselinck, et al.
JCO Precision Oncology
|
February 1, 2022
Combined PIK3CA and FGFR Inhibition With Alpelisib and Infigratinib in Patients With PIK3CA-Mutant Solid Tumors, With or Without FGFR Alterations
David M Hyman, Ben Tran, Luis Paz-Ares, et al.
Clinical Genitourinary Cancer
|
August 8, 2021
A Prospective Multicenter Evaluation of Initial Treatment Choice in Metastatic Renal Cell Carcinoma Prior to the Immunotherapy Era: The MaRCC Registry Experience
Brian A Costello, Nrupen A Bhavsar, Yousef Zakharia, et al.
Page
of 18